Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of Citius Pharmaceuticals, Inc. from 30 Sep 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
Summary
Citius Pharmaceuticals, Inc. quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest in USD history and change rate from 30 Sep 2014 to 31 Dec 2025.
  • Citius Pharmaceuticals, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending 31 Dec 2025 was $93,467,970, a 36% increase year-over-year.
Source SEC data
View on sec.gov
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Change (%)

Citius Pharmaceuticals, Inc. Quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $93,467,970 +$24,548,511 +36% 31 Dec 2025 10-Q 13 Feb 2026 2026 Q1
Q3 2025 $77,527,600 +$3,425,770 +4.6% 30 Sep 2025 10-Q 13 Feb 2026 2026 Q1
Q2 2025 $67,560,930 -$18,723,349 -22% 30 Jun 2025 10-Q 12 Aug 2025 2025 Q3
Q1 2025 $63,575,792 -$16,391,159 -20% 31 Mar 2025 10-Q 12 Aug 2025 2025 Q3
Q4 2024 $68,919,459 -$16,415,175 -19% 31 Dec 2024 10-Q 13 Feb 2026 2026 Q1
Q3 2024 $74,101,830 -$17,329,658 -19% 30 Sep 2024 10-Q 13 Feb 2026 2026 Q1
Q2 2024 $86,284,279 +$86,185,979 30 Jun 2024 10-Q 12 Aug 2025 2025 Q3
Q1 2024 $79,966,951 -$11,839,567 -13% 31 Mar 2024 10-Q 12 Aug 2025 2025 Q3
Q4 2023 $85,334,634 -$15,699,047 -16% 31 Dec 2023 10-Q 12 Aug 2025 2025 Q3
Q3 2023 $91,431,488 -$11,994,757 -12% 30 Sep 2023 10-K 23 Dec 2025 2025 FY
Q2 2023 $98,300* -$110,237,690 30 Jun 2023 10-Q 12 Aug 2024 2024 Q3
Q1 2023 $91,806,518 -$26,389,427 -22% 31 Mar 2023 10-Q 12 Aug 2024 2024 Q3
Q4 2022 $101,033,681 -$23,524,320 -19% 31 Dec 2022 10-Q 12 Aug 2024 2024 Q3
Q3 2022 $103,426,245 -$29,356,488 -22% 30 Sep 2022 10-K 27 Dec 2024 2024 FY
Q2 2022 $110,335,990 -$26,945,963 -20% 30 Jun 2022 10-Q 14 Aug 2023 2023 Q3
Q1 2022 $118,195,945 -$7,566,221 -6% 31 Mar 2022 10-Q 14 Aug 2023 2023 Q3
Q4 2021 $124,558,001 +$98,757,160 +383% 31 Dec 2021 10-Q 14 Aug 2023 2023 Q3
Q3 2021 $132,782,733 +$99,112,065 +294% 30 Sep 2021 10-K 29 Dec 2023 2023 FY
Q2 2021 $137,281,953 +$108,539,891 +378% 30 Jun 2021 10-Q 11 Aug 2022 2022 Q3
Q1 2021 $125,762,166 +$100,544,259 +399% 31 Mar 2021 10-Q 11 Aug 2022 2022 Q3
Q4 2020 $25,800,841 +$2,649,849 +11% 31 Dec 2020 10-Q 11 Aug 2022 2022 Q3
Q3 2020 $33,670,668 +$6,517,796 +24% 30 Sep 2020 10-Q 11 Aug 2022 2022 Q3
Q2 2020 $28,742,062 30 Jun 2020 10-Q 12 Aug 2021 2021 Q3
Q1 2020 $25,217,907 31 Mar 2020 10-Q 12 Aug 2021 2021 Q3
Q4 2019 $23,150,992 31 Dec 2019 10-Q 12 Aug 2021 2021 Q3
Q3 2019 $27,152,872 30 Sep 2019 10-K 15 Dec 2021 2021 FY
Q4 2014 $823,546 31 Dec 2014 10-Q 17 Feb 2015 2015 Q1
Q3 2014 $741,935 30 Sep 2014 10-Q 17 Feb 2015 2015 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.